Please use this identifier to cite or link to this item:
Title: Newly developed effective anti-cancer drugs targeting multiple myeloma
Authors: Sze, DMY
Hou, J
Zhou, L
Keywords: Myeloma
Issue Date: 2008
Publisher: John Wiley & Sons
Source: Drug Development Research, 2008, v. 69, no. 7, p. 451-459 How to cite?
Journal: Drug Development Research 
Abstract: Multiple myeloma (MM) is considered predominantly a cancer of the elderly with a median patient age of 60–65 years at diagnosis and 88% of patients being over 55 years. The disease has remained incurable with a mean survival period of about 3 years for the last 30 years. In the last decade, three useful cancer drugs, namely, thalidomide, lenalidomide, and bortezomib, have been approved by the FDA to append the armamentarium of MM chemotherapy other than the standard combination of melphalan and prednisone that have been used since the 1960 s. Many clinical trials supported by in vitro laboratory investigations have been conducted to understand both the efficacy and mechanisms of the action of these cancer drugs. This brief review aims to provide an overview of new cancer drugs targeting MM and discuss the development of novel strategies for targeting this incurable disease.
ISSN: 0272-4391 (print)
1098-2299 (online)
DOI: 10.1002/ddr.20275
Appears in Collections:Journal/Magazine Article

View full-text via PolyU eLinks SFX Query
Show full item record

Page view(s)

Last Week
Last month
Citations as of Aug 12, 2018

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.